Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of esomeprazole therapy in GERD
2008-001302-16Phase 4Completed
- Sponsor
- Medical Faculty Magdeburg
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esomeprazole in gastroesophageal reflux disease (GERD) and reflux oesophagitis, sponsored by Medical Faculty Magdeburg. Primary endpoints: Intragastric acid suppression and Stereoselective pharmacokinetics of esomeprazole. Started Apr 2008; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)reflux oesophagitis
Beyond the preview
Go deeper on 2008-001302-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001302-16.